29 de março de 2024

Quetiapine blocks cocaine-induced enhancement of brain stimulation reward.

28 de novembro de 20094min1

Behav Brain Res. 2009 Nov 23.

Quetiapine blocks cocaine-induced enhancement of brain stimulation reward.

Gallo A, Lapointe S, Stip E, Potvin S, Rompré PP

Centre de Recherche Fernand-Seguin, Hôpital Louis-H. Lafontaine et Département de Psychiatrie, Université de Montreal, Montréal, (Quebec) Canada H1N 3V2.

Quetiapine is an effective atypical antipsychotic medication that was reported to reduce substance use and craving in patients with schizophrenia. This clinical effect of quetiapine is hypothesized to be due to its low affinity for dopamine receptors and its weak attenuation of central reward functions. The present study was designed to determine the magnitude of the reward attenuation induced by different doses of quetiapine and its effectiveness at reducing the effect of cocaine. Experiments were performed on male Sprague-Dawley rats that were trained to produce operant responses to receive rewarding stimulations to the medial forebrain bundle. In a first study, we tested the effects of three doses of quetiapine (5, 10, 20mg/kg) on brain stimulation reward using a within-subject design and the curve-shift method. In a second study, we tested the effectiveness of a low and high dose of quetiapine (5 and 20mg/kg) at blocking the reward enhancing effect of cocaine (4mg/kg) in different groups of animals. Quetiapine produced a weak (20%) but significant attenuation of reward. Cocaine enhanced reward by 20% and the combination of cocaine with the high dose of quetiapine lead to cancellation of each drug effect. The low dose of quetiapine did not alter baseline reward but completely blocked the effect of cocaine. The magnitude of the reward attenuation induced by quetiapine is consistent with its low affinity for dopamine receptors. It actions on dopamine and non-dopamine neurotransmission are likely to account for its effectiveness at blocking the enhancement of reward by cocaine.

PMID: 19941909 [PubMed – as supplied by publisher]

Supplemental Content

Patient drug information

• Quetiapine (Seroquel®)

Quetiapine is used to treat the symptoms of schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions). It is also used to treat episodes of…

• Source: AHFS Consumer Medication Information

Recent activity

Clear Turn Off Turn On

• Quetiapine blocks cocaine-induced enhancement of brain stimulation reward.Quetiapine blocks cocaine-induced enhancement of brain stimulation reward.

• (((cocaine) AND “2009/11/…(((cocaine) AND “2009/11/21 15.00″[MHDA] : “2009/11/28 15.00″[MHDA])) NOT (((((“cocaine”[TIAB] OR “cocaine”[TIAB]))) AND “0001”[EDAT] : “2009/11/21 15.00″[EDAT]))(36)

Your browsing activity is empty.

Activity recording is turned off.

NIH DHHS USA.gov

Copyright | Disclaimer | Privacy | Accessibility | Contact

National Center for Biotechnology Information , U.S. National Library of Medicine 8600 Rockville Pike, Bethesda MD, 20894 USA


Sobre a UNIAD

A Unidade de Pesquisa em álcool e Drogas (UNIAD) foi fundada em 1994 pelo Prof. Dr. Ronaldo Laranjeira e John Dunn, recém-chegados da Inglaterra. A criação contou, na época, com o apoio do Departamento de Psiquiatria da UNIFESP. Inicialmente (1994-1996) funcionou dentro do Complexo Hospital São Paulo, com o objetivo de atender funcionários dependentes.



Newsletter


    Skip to content